The most relevant papers / abstracts published in 2023. Novelties and Guidelines and also published protocols of interesting trials. Breast cancer highlights from 2023: Knowledge to guide practice and future research - The Breast thebreastonline.com/article/S0960-…

Very useful reading for reviewing 2023 and planning the new year!!! Maria-Joao Cardoso

Moving to ultra-short therapy to cure patients with cancer: a solution for sustainable cancer care. Don’t miss the editorial by Drs. Ribeiro, Dixon-Douglas and FabriceAndre that accompanies the latest issue of ESMO Open. esmoopen.com/article/S2059-…

ESMO Open FabriceAndre JoanaMRibeiro2

💭Ultra-short treatments offer promising avenues for improving cancer care efficiency. While challenges persist, such as personalisation & innovative trial designs, the potential benefits for patients are significant. An interesting editorial: ow.ly/xvtj50QBCSR #MedEd

We are so lucky to have you as a mentor Ines Vaz Luis congratulations 🎉🎉⭐️

Another #ESMObreast24...Another science productive and awarded year for BreastUnit_DMO Gustave Roussy Gustave Roussy Cancer Survivorship Group team! Barbara Pistilli Suzette delaloge Elie Rassy @JZeghondi Federica Giugliano, MD Thomas Grinda Ines Vaz Luis Julia Dixon-Douglas Fernanda Mosele Antonio Di Meglio, MD, PhD Martina Pagliuca

Chairing an Oxford discussion on Ki67 at the Annual German Senology Conference. Amazing to see that about 70% of the breast centers use endocrine response assessment in clinical routine according to WSG ADAPT. #OncoAlert

🇪🇺🇪🇺🇪🇺🇪🇺🇪🇺🇪🇺🇪🇺🇪🇺🇪🇺🇪🇺🇪🇺🇪🇺🇪🇺 🇪🇺🇪🇺🇪🇺🇪🇺🇪🇺🇪🇺🗳️🇪🇺🇪🇺🇪🇺🇪🇺🇪🇺🇪🇺 🇪🇺🇪🇺🇪🇺🇪🇺🗳️🇪🇺 V 🇪🇺🗳️🇪🇺🇪🇺🇪🇺🇪🇺 🇪🇺🇪🇺🇪🇺🗳️🇪🇺🇪🇺 O 🇪🇺🇪🇺🗳️🇪🇺🇪🇺🇪🇺 🇪🇺🇪🇺🇪🇺🗳️🇪🇺🇪🇺 T 🇪🇺🇪🇺🗳️🇪🇺🇪🇺🇪🇺 🇪🇺🇪🇺🇪🇺🇪🇺🗳️🇪🇺 E 🇪🇺🗳️🇪🇺🇪🇺🇪🇺🇪🇺 🇪🇺🇪🇺🇪🇺🇪🇺🇪🇺🇪🇺🗳️🇪🇺🇪🇺🇪🇺🇪🇺🇪🇺🇪🇺 🇪🇺🇪🇺🇪🇺🇪🇺🇪🇺🇪🇺🇪🇺🇪🇺🇪🇺🇪🇺🇪🇺🇪🇺🇪🇺 #UseYourVote

Ao cuidado das ovelhas e carneiros de todo o mundo

Dia de eleições! Para os portugueses em Paris, muito fácil votar no consulado! Até 19h basta o cartão cidadão!!!

After last night elections....

Congrats Veerle Geurts and TILs Working Group. Why is this JAMA Oncology paper important? Its known that TILs are progn in TNBC and that not all stage I TNBC pts benefit from chemo.👇we show that pT1cN0 pts with high TILs have excel survival without chemo! The Netherlands Cancer Institute

Waiting for the olympic flame.....

1/1 Today ✍️ Journal of Clinical Oncology Sometimes treating TNBC can be challenging. Nowadays, academic clin res to improve treatm for TNBC can also be challenging. How do we get from one-size fits all with 4 types of chemo plus 1yr of pembro to a personalized treatm? ascopubs.org/doi/10.1200/JC…

Thanks Dana-Farber’s Breast Oncology Center for highlighting our recent Commentary paper Journal of Clinical Oncology

What is the impact of immune checkpoint inhibitors in the outcome of patients with early breast cancer? Check out this huge work led by Guillermo Villacampa and Tomás Pascual Treatment tailoring is paramount to improve patient care! ESMO - Eur. Oncology OncoAlert Vall d’Hebron Institute of Oncology (VHIO) ASCO

👏👏👏 for Myriam Chalabi and NICHE2 team The Netherlands Cancer Institute. The KM ‘curve’ doesnt apply here its a line ate 100% survival, unprecedented! Congrats!

Benjamin Besse d.planchard Fabrice Barlesi ESMO - Eur. Oncology Pierre Blanchard, MD Ines Vaz Luis 🔹 OPT-PEMBRO trial led by Dr Joana Ribeiro Gustave Roussy is a model of tailored perioperative trial in Breast Cancer highlighted at #ESMO24 Presidential Session. JoanaMRibeiro2 ESMO - Eur. Oncology

Very nice discussions about almost every aspect you can think about in BC management! Hope Rugo , @valentinaguarneri, Stephen, @carlosbarrios! @metebalfoheidi!